Keyphrases
Pancreatic Cancer
75%
Mucin
75%
Gemcitabine
75%
Afatinib
69%
EGFR Family
41%
Pancreatic Cancer Cells
33%
Intrinsic Resistance
24%
Tumor Microenvironment
24%
Family Members
24%
Stem Cell Microenvironment
22%
Chemotherapy Resistance
16%
Cancer Patients
16%
Cytotoxic Agents
16%
Disease Progression
16%
Pancreatic Cancer Stem Cells
16%
Family Protein
16%
Signaling Pathway
16%
Genetically Engineered Mouse Models
8%
EGFR Inhibitors
8%
Therapeutic Regimen
8%
Mechanism of Action
8%
Specific Inhibitor
8%
Irreversible Inhibitor
8%
Cancer Causes
8%
Effective Therapy
8%
First-line Chemotherapy
8%
Chemoresistance
8%
Therapeutic Tool
8%
Specific Intent
8%
Cancer Mortality
8%
Targeted Therapeutics
8%
Targeting Cancer Stem Cells
8%
ErbB
8%
Tumor Targeting
8%
Enhanced Antitumor Efficacy
8%
Clinical Trials
8%
Functional Impact
8%
Chemotherapy Efficacy
8%
Potential Impact
8%
Functiona
8%
Combination Therapy
8%
Combinational Approaches
8%
Medicine and Dentistry
Epidermal Growth Factor Receptor
100%
Mucin
100%
Pancreas Cancer
100%
Gemcitabine
81%
Afatinib
74%
Cancer Cell
36%
Tumor Microenvironment
27%
Protein Family
18%
Signal Transduction
18%
Cytotoxic Agent
18%
Pancreatic Cancer Stem Cell
18%
Disease Exacerbation
18%
Chemotherapy
18%
First-Line Chemotherapy
9%
Malignant Neoplasm
9%
Combination Therapy
9%
Drug Resistance
9%
Clinical Trial
9%
ErbB
9%
Cancer Stem Cell
9%
Downregulation
9%
Antiinfective Agent
9%
In Vitro
9%
EGFR Inhibitors
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Mucin
100%
Epidermal Growth Factor Receptor
100%
Gemcitabine
69%
Afatinib
63%
Tumor Microenvironment
23%
Intrinsic Resistance
23%
Cytotoxic Agent
15%
Malignant Neoplasm
15%
Disease Exacerbation
15%
Combination Therapy
7%
First-Line Chemotherapy
7%
Drug Resistance
7%
Clinical Trial
7%
Mouse Model
7%
Genetically Engineered Mouse Strain
7%
Antiinfective Agent
7%